Trials / Completed
CompletedNCT00073502
Phase II Study of Single Agent OSI-7904L in Patients With Gastric or Gastroesophageal (GEJ) Cancer
A Phase II Study of Single Agent OSI-7904L In Patients With Locally Advanced or Metastatic Adenocarcinoma Of the Stomach or Gastroesophageal Junction
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 43 (planned)
- Sponsor
- OSI Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Multi-center, open-label, non-randomized Phase II study to evaluate the efficacy and safety of OSI-7904L in gastric and GEJ cancers. Those patients who do not derive clinical benefit after two cycles may be switched to a commonly used combination regimen.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | OSI-7904L |
Timeline
- Start date
- 2003-10-01
- Completion
- 2003-10-01
- First posted
- 2003-11-25
- Last updated
- 2006-02-22
Locations
11 sites across 3 countries: United States, Belgium, United Kingdom
Source: ClinicalTrials.gov record NCT00073502. Inclusion in this directory is not an endorsement.